Prospects for overcoming maturational and genetic barriers to the human antibody response to the capsular polysaccharide of Haemophilus influenzae type b.
The isolated capsular polysaccharide induces antibody protective against invasive infections by H. influenzae b. Maturation of responsiveness is slow such that infants are not protected. Several protein-coupled versions of the antigen are being tested for immunogenicity in early infancy. The relation of structure to immunogenicity is not completely defined, but all induce a booster-type antibody response with protective potential. Primary vaccination in infancy appears to mimic natural priming, activating clones of B lymphocytes that can later be restimulated by uncoupled polysaccharide. Prospects appear good for immunizing normal infants and also children with immunoregulatory defects predisposing to infection.